TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
Rohit Loomba, Rizwana Mohseni, K Jean Lucas, Julio A Gutierrez, Robert G Perry, James F Trotter, Robert S Rahimi, Stephen A Harrison, Veeral Ajmera, Jeffrey D Wayne, Marie O'Farrell, William McCulloch, Katharine Grimmer, Mary Rinella, Vincent Wai-Sun Wong, Vlad Ratziu, Gregory J Gores, Brent A Neuschwander-Tetri, George Kemble, Rohit Loomba, Rizwana Mohseni, K Jean Lucas, Julio A Gutierrez, Robert G Perry, James F Trotter, Robert S Rahimi, Stephen A Harrison, Veeral Ajmera, Jeffrey D Wayne, Marie O'Farrell, William McCulloch, Katharine Grimmer, Mary Rinella, Vincent Wai-Sun Wong, Vlad Ratziu, Gregory J Gores, Brent A Neuschwander-Tetri, George Kemble
Abstract
Background & aims: Increased de novo lipogenesis creates excess intrahepatic fat and lipotoxins, propagating liver damage in nonalcoholic steatohepatitis. TVB-2640, a fatty acid synthase inhibitor, was designed to reduce excess liver fat and directly inhibit inflammatory and fibrogenic pathways. We assessed the safety and efficacy of TVB-2640 in patients with nonalcoholic steatohepatitis in the United States.
Methods: 3V2640-CLIN-005 (FASCINATE-1) was a randomized, placebo-controlled, single-blind study at 10 US sites. Adults with ≥8% liver fat, assessed by magnetic resonance imaging proton density fat fraction, and evidence of liver fibrosis by magnetic resonance elastography ≥2.5 kPa or liver biopsy were eligible. Ninety-nine patients were randomized to receive placebo or 25 mg or 50 mg of TVB-2640 (orally, once-daily for 12 weeks). The primary end points of this study were safety and relative change in liver fat after treatment.
Results: Liver fat increased in the placebo cohort by 4.5% relative to baseline; in contrast TVB-2640 reduced liver fat by 9.6% in the 25-mg cohort (n = 30; least squares mean: -15.5%; 95% confidence interval, -31.3 to -0.23; P = .053), and 28.1% in the 50-mg cohort (n = 28; least squares mean: -28.0%; 95% confidence interval, -44.5 to -11.6; P = .001). Eleven percent of patients in the placebo group achieved a ≥30% relative reduction of liver fat compared to 23% in the 25-mg group, and 61% in the 50-mg group (P < .001). Secondary analyses showed improvements of metabolic, pro-inflammatory and fibrotic markers. TVB-2640 was well tolerated; adverse events were mostly mild and balanced among the groups.
Conclusions: TVB-2640 significantly reduced liver fat and improved biochemical, inflammatory, and fibrotic biomarkers after 12 weeks, in a dose-dependent manner in patients with nonalcoholic steatohepatitis. ClinicalTrials.gov, Number NCT03938246.
Keywords: PRO-C3; Palmitate.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed